? ÊàŦÑ×£¨Arthritis£©
? ¼¡Î®ËõÐÔ¼¹Ëè²àË÷Ó²»¯Ö¢£¨Amyotrophic Lateral Sclerosis, ALS£©
? ÒøÐ¼²¡£¨Psoriasis£©
? ÌØÓ¦ÐÔÆ¤Ñ×£¨Atopic Dermatitis, AD£©
? Ñ×Ö¢ÐÔ³¦²¡£¨Inflammatory Bowel Disease, IBD£©
01 ½ºÔÓÕµ¼µÄÊàŦÑ×Ä£×Ó
Àà·çʪÐÔÊàŦÑ×£¨Rheumatoid Arthritis, RA£©¶¯ÎïÄ£×Ó¹ØÓÚÑо¿ÌåÄÚRAµÄ·¢²¡»úÖÆºÍÆÀ¼Û¿¹RAÒ©ÎïµÄÁÆÐ§ÖÁ¹ØÖ÷Òª¡£
½ºÔÓÕµ¼µÄÊàŦÑ×£¨Collagen Induced Arthritis, CIA£©ÓëÈËÀàÀà·çʪÊàŦÑ×¾ßÓÐÅäºÏµÄÃâÒßѧºÍ²¡ÀíÑ§ÌØÕ÷£¬Òò´Ë±»ÆÕ±éÓ¦ÓÃÓÚÖ²¡»úÀíºÍÐÂҩҩЧµÄÑо¿¡£¢òÐͽºÔÂѰף¨C¢ò£©Äܹ»ÃâÒßÓÕµ¼Ò׸ÐÄö³Ý¶¯ÎïºÍ·ÇÈËÁ鳤ÀදÎïÌåÄÚ±¬·¢ÊàŦÑ×ÐÔ×ÓµÄ×ÔÉíÃâÒß·´Ó¦¡£
±ðµÄ£¬CIAµÄÒ׸ÐÐÔÒ²ÓëRAÏàËÆ£¬ºÍÖ÷Òª×éÖ¯ÏàÈÝÐÔ¸´ºÏÌ壨Major Hhistocompatibility Complex, MHC£©µÄ¢òÀà·Ö×ÓÓйء£ÃâÒß·´Ó¦µÄÌØµãÊÇ£º´Ì¼¤½ºÔÌØÒìÐÔTϸ°û£¬±¬·¢Õë¶ÔÐÔÃâÒß¿¹Ô£¨ÒìÔ´C¢ò£©ºÍ×ÔÉí¿¹Ô£¨Ð¡Êó»ò´óÊóC¢ò£©µÄ¸ßµÎ¶ÈÌØÒìÐÔ¿¹Ìå¡£
02 ÍêÈ«¸¥ÊÏ×ô¼ÁÓÕµ¼µÄÊàŦÑ×Ä£×Ó
Àà·çʪÐÔÊàŦÑ×£¨RA£©ÊÇÒ»ÖÖÂýÐÔ¾ÙÐÐÐÔµÄÑ×Ö¢ÐÔÊàŦÑס£ÍêÈ«¸¥ÊÏ×ô¼Á£¨Complete Freund¡¯s Adjuvant, CFA£©ÓÕµ¼µÄÊàŦÑ×Ä£×ÓÄܹ»ÌåÏÖ³ö°éÓÐÈ«ÉíÐԸıäµÄÒ»Á¬ÐÔÑ×Ö¢£¬ÒÔ¼°»¬Ä¤ÔöÉú¡¢½ÇĤÒí¡¢¶ú²¿ºÍβ²¿·ºÆð¡°ÊàŦÑס±½á½ÚµÈ£¬ÓëÈËÀàÊàŦÑ×ÓжàÖÖÏàËÆÖ®´¦£¬Òò´ËÊÇÒ»¸öºÜÊÇÊÊÊÊÓÃÓÚ·¢²¡»úÀíµÄÑо¿ºÍÐÂҩҩЧÆÀ¼ÛµÄÄ£×Ó¡£
CFAÊÇÓÉʯÀ¯ÓͺͶþËõ¸Ê¶´¼Ò»ÓÍËáÓëÈÈÃð»î½áºË·ÖÖ¦¸Ë¾ú»ìÏý¶ø³ÉµÄ»ìÏýÈéÒº£¬ÔÚÄö³ÝÀදÎïµÄצ²¿Æ¤ÏÂ×¢Éä»ò¸¹Ç»×¢É䣬´Ó¶øÓÕµ¼¶¯Îï¶àÆ÷¹ÙµÄÃâÒßÑ×Ö¢·´Ó¦¡£
CFAÓÕµ¼µÄ´óÊóÊàŦÑ×£¨Adjuvant Induced Arthritis, AIA£©Ó¦ÓÃÆÕ±é£¬¶ÔÑо¿Ñ×Ö¢Àú³ÌµÄ²¡Àí¡¢ÐÄÀíºÍÒ©Àí×÷Óã¬ÒÔ¼°ÆÀ¹ÀÒ©ÎïµÄÕòʹDZÁ¦»ò¿¹Ñ××÷ÓþßÓÐÖ÷ÒªÒâÒå¡£
03 ÄòËáÄÆÓÕµ¼µÄÍ´·çÐÔÊàŦÑ×Ä£×Ó
Í´·çÐÔÊàŦÑ×£¨Gouty Arthritis, GA£©µÄÖ÷ÒªÌØÕ÷ÊÇ£ºÄòËáÄÆ£¨Monosodium Urate, MSU£©¾§ÌåÔÚÊàŦÖÜΧ×éÖ¯³Á»ý£¬´Ì¼¤ÊàŦ£¬ÒýÆðÊàŦ»¬Ä¤¼°ÖÜΧ×éÖ¯²¡Ëð¼°Ñ×Ö¢·´Ó¦¡£ÁÙ´²ÖУ¬Í´·çµÄ·¢²¡Åãͬ×ÅÊàŦÖÜΧ×éÖ¯»òÊàŦµÄ´¥Í´¡¢ºì°ß¡¢·¢ºì¡¢Ö×ÕÍ¡¢ÌÛÍ´ºÍ·¢ÈÈ¡£
ÏÖÔÚ£¬GA±¬·¢Ó뻺½âµÄÏêϸ»úÖÆÉÐδÃ÷È·£¬µ«Ñо¿Ö°Ô±ÆÕ±éÒÔΪ£¬ÊàŦ²¿Î»Îö³öµÄMSU¾§ÌåÊÇÔì³ÉÍ´·çÐÔÊàŦÑ×µÄÒªº¦»¯Ñ§ÎïÖÊ¡£MSU¾§ÌåÄܹ»ÓÕ·¢×ÔÉíÃâÒß¼°Ñ×Ö¢·´Ó¦£¬¹ú¼ÊÉϳ£±»ÓÃÓÚÓÕµ¼¼±ÐÔÍ´·çÐÔÊàŦÑ×Ä£×Ó£¬Òѱ»ÆÕ±éÓ¦ÓÃÓÚÒ©Àí¡¢Ò©Ð§µÈ·½ÃæµÄÑо¿¡£
04 ʵÑéÐÔ×ÔÉíÃâÒßÐÔÄÔ¼¹ËèÑ×Ä£×Ó
¶à·¢ÐÔÓ²»¯Ö¢£¨Multiple Sclerosis, MS£©ÊÇÒ»ÖÖÖÐÊàÉñ¾ÏµÍ³£¨Central Nervous System, CNS£©µÄÑ×Ö¢ÐÔ¼²²¡£¬ÊµÑéÐÔ×ÔÉíÃâÒßÐÔÄÔ¼¹ËèÑ×£¨Experimental autoimmune encephalomyelitis, EAE£©ÊÇMS×î³£¼ûµÄ¶¯ÎïÄ£×ÓÖ®Ò»¡£
MSµ¼ÖµÄÃâÒßϵͳ¹¥»÷»áʹËèÇÊÊÜËð£¬×ÌÈÅÉñ¾´«µ¼£¬½ø¶øµ¼ÖÂһϵÁÐÖ¢×´£¬°üÀ¨ÊÓÁ¦ÊÜËð¡¢¼¡ÈâÎÞÁ¦¡¢Ðµ÷ÄÜÁ¦È±Ê§ºÍÈÏÖª¹¦Ð§Õϰ¡£ÆäÌØÕ÷ÊÇÉñ¾Ñ×Ö¢¼°ÅãͬµÄÍÑËèÇʺÍÖáÍ»±äÐÔ¡£
ÔÚEAEСÊóÄ£×ÓÖУ¬Í¨¹ýÓÕµ¼×ÔÉíÃâÒß·´Ó¦£¬Ê¹µÃTϸ°ûºÍµ¥ºËϸ°û½þÈó½øÈëÖÐÊàÉñ¾ÏµÍ³£¬µ¼ÖÂÖáÍ»µÄÈ¥ËèÇÊ»¯£¬½ø¶øÒýÆðÉñ¾´«µ¼ÕϰºÍ¾ÙÐÐÐÔºó̱֫»¾£¬Äܹ»Ä£ÄâMSµÄ²¡ÀíÌØÕ÷Óë¼²²¡Ï£Íû¡£
±ðµÄ£¬EAE³£±»ÓÃ×÷ϸ°û½éµ¼µÄÆ÷¹ÙÌØÒìÐÔ×ÔÉíÃâÒß¼²²¡Ä£×Ó¡£EAE»¹¾ßÓÐÖØ´óµÄÉñ¾Ò©Àíѧ£¬Ðí¶àÓÃÓÚMSÒ©Îï¶¼ÊÇÔÚEAEÄ£×ӵĻù´¡ÉÏ¿ª·¢¡¢²âÊÔ¡¢ÑéÖ¤µÄ¡£
05 ßäàÄªÌØÓÕµ¼µÄÒøÐ¼²¡Ä£×Ó
ÒøÐ¼²¡ÊÇÒ»ÖÖÂýÐÔÑ×Ö¢ÐÔÆ¤·ô²¡£¬Óë×ÔÉíÃâÒß¹¦Ð§ÔÓÂҵȶàÖÖÓÕÒòÓйء£ÒøÐ¼²¡»áµ¼ÖÂÆ¤·ôÒòËØµÄ¸Ä±ä£¬ÏÖÔÚÆÕ±éÒÔÎªÒøÐ¼²¡ÊÇÒ»ÖÖÃâÒßϸ°û¼°ÃâÒßÏà¹ØÏ¸°ûÅäºÏ½éµ¼µÄÑ×Ö¢ÐÔÆ¤·ô²¡¡£
ßäàÄªÌØ£¨Imiquimod, IMQ£©ÓÕµ¼µÄСÊóÄ£×ÓÊÇÊܵ½ÆÕ±éÈϿɵÄÒøÐ¼²¡ÀදÎïÄ£×ÓÖ®Ò»¡£IMQÊÇTollÑùÊÜÌ壨TLR£©7/8µÄÅäÌå¡£ÓÉÓÚTLRsÂþÑÜÓÚ¾ÞÊÉϸ°û¡¢µ¥ºËϸ°ûºÍ½¬Ï¸°ûÑùÊ÷ͻϸ°û£¨pDC£©ÉÏ£¬Òò´ËIMQÄܹ»Ç¿ÁÒ¼¤»îÃâÒßϵͳ¡£¾Ö²¿Ê¹ÓÃIMQ¿ÉÓÕµ¼ÒøÐ¼²¡£¬Äܹ»½ÏºÃµØÄ£ÄâÈËÀàÒøÐ¼²¡ÑùµÄƤËðÌåÏÖ£¬²¢Ò»¶¨Ë®Æ½µØ±£´æÓëÒøÐ¼²¡ÏàËÆµÄ¹ÌÓÐÃâÒߺͻñµÃÐÔÃâÒßÔÓÂÒ£¬¿ÉÓÃÓÚÑо¿ÒøÐ¼²¡Ç±ÔÚ»úÖÆºÍÆÀ¹ÀÐÂÁÆ·¨¡£
06 IL-23ÓÕµ¼µÄСÊó¶úÀªÒøÐ¼²¡Ä£×Ó
IL-23£¨°×ϸ°û½éËØ-23£©ÊÇÒ»ÖÖÒìÔ´¶þ¾ÛÌåϸ°ûÒò×Ó£¬ÓÉp19ÑÇ»ù£¨IL-23¶ÀÍÌ£©ºÍp40ÑÇ»ù£¨ÓëIL-12¹²Ïí£©Í¨¹ý¶þÁò¼üÅþÁ¬Ðγɡ£IL-23/Th17ͨ·ÊÇÒøÐ¼²¡µÄÖ÷ÒªÖ²¡Í¨Â·¡£IL-23Äܹ»Ôö½øTh17ϸ°ûµÄ·Ö½â£¬±¬·¢IL-17A¡¢IL-17F¼°IL-22µÈϸ°ûÒò×Ó£¬´Ó¶øµ¼Ö½ÇÖÊÐγÉϸ°ûÒì³£·Ö½âºÍÑ×Ö¢¡£ÆäÖУ¬IL-23/IL-17Aͨ·ÔÚÒøÐ¼²¡ÖÐÆð×ÅÖÁ¹ØÖ÷ÒªµÄ×÷Óá£
IL-23×¢ÉäÄ£×ÓµÄÓÅÊÆÔÚÓÚʹÓüòµ¥Ï¸°ûÒò×Ó£¬²¢ÇÒÕâÖÖϸ°ûÒò×ÓÔÚÒøÐ¼²¡ÖÐÒý·¢Ñ×Ö¢µÄ×÷ÓÃÒÑ»ñµÃ֤ʵ¡£¾Æ¤ÄÚ×¢ÉäIL-23¿ÉÒÔÓÕµ¼Ð¡Ê󱬷¢ÒøÐ¼²¡ÑùƤ·ô²¡±ä£¬½¨Éè±ã½ÝÇÒ±¾Ç®½ÏµÍ£¬±»ÆÕ±éÓÃÓÚÈËÀàÒøÐ¼²¡Ñо¿¡£
07 ·ð²¨õ¥ÓÕµ¼µÄ¼±ÐÔʪÕîÑùÄ£×Ó
ÌØÓ¦ÐÔÆ¤Ñ×£¨Atopic Dermatitis, AD£©µÄÓÕÒòÖØ´ó¶àÑù£¬ÆäÁÙ´²ÌåÏÖ°üÀ¨Æ¤·ô¸ÉÔʪÕîÑùƤË𣨰üÀ¨ºì°ß¡¢ÉøÍ¸ºÍ½áð衢̦޺Ñù±äµÈ£©ÒÔ¼°Ç¿ÁÒðþÑ÷µÈµÈ¡£Èç²»¼ÓÒÔ¿ØÖÆ£¬ÕâЩÑ×Ö¢·´Ó¦¿ÉÄÜ»áת±äΪ¸üÄÑÒÔ½â¾öµÄ¼²²¡¡£
ÏÖÔÚ£¬ÌÇÆ¤Öʼ¤ËØ¡¢·ÇçÞÌ忹Ñ×Ò©µÈÊÇ¿ØÖÆÑ×Ö¢µÄÊ×Ñ¡¡£µ«Àà¹Ì´¼Ò©ÎïʹÓò»µ±£¬»áÅãͳһ¶¨Ë®Æ½µÄ¸±×÷Óá£ÒÔÊÇ£¬¿ª·¢ÖÎÁÆÑ×Ö¢µÄÐÂÒªÁì¾ßÓÐÖ÷ÒªµÄÁÙ´²ÒâÒå¡£
ÔÚɸѡDZÔÚ¿¹Ñ×Ò©Îïʱ£¬·ð²¨õ¥ÓÕµ¼µÄСÊóÄ£×Ó¿ÉÒԽϺõػ¹ÔÑ×Ö¢·´Ó¦£¬³£±»ÓÃÓÚÑо¿¿¹Ñ×Ò©ÎïÔÚÎÞ¾úÐÔÑ×Ö¢ÖеÄҩЧ¡£±ðµÄ£¬·ð²¨õ¥Ò²³£ÓÃÓÚ½¨Éè¼±ÐÔʪÕîÑùÄ£×Ó¡£
08 DNFBÓÕµ¼µÄÑǼ±ÐÔʪÕîÑùÄ£×Ó
ÔÚÌØÓ¦ÐÔÆ¤Ñ×£¨AD£©Ñо¿ÖУ¬¿ÆÑÐÖ°Ô±ÔøÊµÑéͨ¹ý·Û³¾òý£¨Dermatophagoides farinae, Df/Derf£©×÷Ϊ¹ýÃôÔ½¨ÉèADСÊóÄ£×Ó¡£µ«ÔÚBALB/cСÊóÉíÉÏ±íÆ¤Í¿Ä¨DfÌáÈ¡ÎDfE£©²¢Ã»ÓÐÓÕµ¼·ºÆðµä·¶µÄƤËð·´Ó¦¡£
2,4-¶þÏõ»ù·ú±½£¨Dinitrofluorobenzene, DNFB£©ÊÇÒ»ÖÖÄܵ¼ÖÂСÊó½Ó´¥ÐÔÆ¤Ñ׵ij£¼ûµ¥Ì壬ÄÜÓëÆ¤·ô×éÖ¯ÂѰ×Á¬Ïµ³ÉΪÍêÈ«¿¹Ô£¬¼¤»îTÁܰÍϸ°û£¬Òý·¢¹ýÃô·´Ó¦¡£DNFBÒý·¢µÄƤ·ô¹¦Ð§Õϰ¿ÉÄÜÊÇÔöÇ¿DfE¶ÔСÊ󯤷ôÓ°ÏìµÄÒ»ÖÖÒªÁì¡£
½»ÌæÊ¹ÓÃDNFBºÍDf´Ì¼¤Æ¤·ô£¬¿ÉÓÕµ¼BALB/cСÊ󱬷¢ÓëÈËÀàADÏàËÆµÄTh2ÐÍÆ¤·ôÑ×Ö¢¡£ÕâÖÖÄ£×Ó¶ÔÑо¿ADµÄ·¢²¡»úÖÆºÍ¿ª·¢ÐÂÐÍÖÎÁÆÒ©ÎïºÜÓмÛÖµ¡£
09 DNFBÓÕµ¼µÄÂýÐÔÌØÓ¦ÐÔÆ¤Ñ×Ä£×Ó
DNFB³£±»ÓÃÀ´½¨ÉèСÊóÌØÓ¦ÐÔÆ¤Ñ×£¨AD£©Ä£×Ó£¬Ëæ×ÅÔìÄ£Àú³Ì·ºÆðƤ·ô¸ÉÔïÍÑм¡¢ºì°ßµÈÂýÐԸı䣬ÓëÈËÀàADƤËðת±äÏàËÆ¡£
ͨ¹ýDNFBÖØ¸´´Ì¼¤¿ÉÒÔ½¨ÉèÂýÐÔÌØÓ¦ÐÔÆ¤Ñ×Ä£×Ó£¬ÓÕµ¼ADÑùƤÑס¢×é֯ѧת±äÒÔ¼°±íƤÆÁÕϹ¦Ð§Õϰ£¬Ñо¿Ç¿ÁÒðþÑ÷ºÍ¸´·¢ÐÔÆ¤ËðµÈÎÊÌâ¡£
10 TNBSÓÕµ¼µÄ´óÊóÀ£ÑñÐԽ᳦Ñ×Ä£×Ó
Ñ×Ö¢ÐÔ³¦²¡£¨Inflammatory bowel disease, IBD£©ÊÇÒ»ÖÖÂýÐÔ³¦µÀÑ×Ö¢ÐÔ¼²²¡£¬°üÀ¨¿ËÂÞ¶÷²¡£¨Crohn's Disease, CD£©ºÍÀ£ÑñÐԽ᳦Ñ×£¨Ulcerative Colitis, UC£©£¬ÏÖÔÚ·¢²¡»úÖÆÉв»Ã÷È·£¬Ö÷ÒªÓëÃâÒßϵͳÒì³£¡¢´ó×Úϸ°û½þÈóÓйأ¬°üÀ¨CD4+ TÁܰÍϸ°û¡¢·Ê´óϸ°û¡¢ÖÐÐÔÁ£Ï¸°ûºÍÊÈËáÐÔÁ£Ï¸°ûÊýÄ¿ÔöÌí¡£ÕâЩÃâÒß·´Ó¦»áÒýÆðÑ×Ö¢¡¢À£Ññ¡¢Ë®Öס¢¸¹Ðº£¨ð¤Òº±ãºÍ/»òŧѪ±ã£©¡¢·¢ÈȺÍ賦È䶯Õϰ¡£ÁÙ´²»¹Ã»ÓÐÕë¶ÔIBDµÄÒ©ÎÏÖÔÚµÄÖ÷ÒªÖÎÁÆÒªÁìÊÇÑÓ»º¼²²¡Ï£Íû¡£
IBD¶¯ÎïÄ£×ÓÄܹ»ÌåÏÖ³öÈËÀàCDºÍUCµÄijЩ²¡/ÐÄÀíÌØÕ÷£¬°üÀ¨ÌåÖØ¼õÇáºÍ¸¹Ðº£¬°éÓÐѪ±ãºÍ/»òÕ³Òº±ã¡¢·¢ÈÈ¡¢½á³¦Ëõ¶Ì¡¢ÒþÎÑÒì³£¡¢Î¸È䶯ÕϰºÍÑ×֢ϸ°û½þÈóµÈ¡£
2,4,6-ÈýÏõ»ù±½»ÇËᣨTNBS£©ÓÕµ¼µÄÄ£×ÓÊÊÓÃÓÚСÊóºÍ´óÊó¡£TNBS´óÊóÀ£ÑñÐԽ᳦Ñ×ÊÇÒ»ÖÖÒÔCD4+ TÁܰÍϸ°û½þÈóÎªÌØÕ÷µÄTh1ÐÍÑ×Ö¢£¬ÓëÈËÀàCDºÍUC¾ßÓÐÏàͬµÄÌØÕ÷¡£
11 ÆÏ¾ÛÌÇÁòËáÄÆÓÕµ¼µÄСÊóÀ£ÑñÐԽ᳦Ñ×Ä£×Ó
ÆÏ¾ÛÌÇÁòËáÄÆ£¨Dextran sulphate sodium, DSS£©ÊÇÒ»ÖÖË®ÈÜÐÔ¡¢´ø¸ºµçºÉ¡¢·Ö×ÓÁ¿¿É±äµÄÁòËữ¶àÌÇ¡£ÓÉÓÚDSS¶Ô½á³¦ÉÏÆ¤Ï¸°ûÓж¾ÐÔ£¬¿ÉÄܵ¼ÖÂճĤÆÁÕϹ¦Ð§ÊÜËð£¬Òò´Ë¸øÐ¡ÊóÒûÓÃDSS¿ÉÒÔÒýÆðÀàËÆÈËÀà¿Ë¡¶÷Êϲ¡µÄÈ«½á³¦²¡Ö¢¡£
DSS½á³¦Ñ×Ä£×Ó¾¼Ã¡¢ÇáÓ¯£¬¿É´ó×ÚÖØ¸´½¨É裬ÔÚIBDÑо¿ÖкÜÊÇÊ¢ÐС£Í¨¹ý¸Ä±äDSSµÄŨ¶ÈºÍÒûÓÃÆµÂÊ£¬¿ÉÒÔ½¨Éè¼±ÐÔ¡¢ÂýÐԺ͸´·¢ÐÔ³¦Ñ×Ä£×Ó¡£
²Î¿¼ÎÄÏ×£º
[1] Jing Luan, et al. Applicability and implementation of the collagen-induced arthritis mouse model, including protocols (Review). Exp Ther Med. 2021 Sep;22(3):939. doi: 10.3892/etm.2021.10371.
[2] Xin Cui, et al. Evaluation of antiarthritic activity of nimbolide against Freund's adjuvant induced arthritis in rats. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3391-3398. doi: 10.1080/21691401.2019.1649269.
[3] Su-Hyun Shin, et al. 1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol (PLAG) Mitigates Monosodium Urate (MSU)-Induced Acute Gouty Inflammation in BALB/c Mice. Front Immunol. 2020 Apr 24:11:710. doi: 10.3389/fimmu.2020.00710.
[4] Cris S Constantinescu, et al. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011 Oct;164(4):1079-106. doi: 10.1111/j.1476-5381.2011.01302.x.
[5] Leslie van der Fits, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009 May 1;182(9):5836-45. doi: 10.4049/jimmunol.0802999.
[6] Shujing Feng, et al. An Atopic Dermatitis-Like Mouse Model by Alternate Epicutaneous Application of Dinitrofluorobenzene and an Extract of Dermatophagoides Farinae. Front Med (Lausanne). 2022 Jun 15:9:843230. doi: 10.3389/fmed.2022.843230.
[7] Benoit Chassaing, et al. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014 Feb 4:104:15.25.1-15.25.14. doi: 10.1002/0471142735.im1525s104.